Literature DB >> 21279152

Hepatitis A, B and nAnB: The Viruses and their Prevention.

G Y Minuk.   

Abstract

THREE VIRUSES COMMONLY INFECT THE LIVER: hepatitis A virus (HAV), hepatitis B virus (HBV) and the virus(es) responsible for non A non B hepatitis (nAnB). HAV infection occurs predominantly by the fecal-oral route and thus is more common in areas where living conditions are poor and personal hygiene suboptimal. Immune serum globulin (ISG) prevents this form of hepatitis. HBV infection can be spread by either parenteral (e.g. drug abuse) or non-parenteral (e.g. intimate contact) routes. High risk, susceptible individuals should be vaccinated with the HBV vaccine for longterm protection. Hepatitis B immune globulin (HBIG) remains the treatment of choice after exposure, but its protective effect does not exceed three to four months. The nAnB agent is spread by the same routes as HBV infection. At present there is no convincing evidence that any form of active or passive prophylaxis is beneficial for this form of hepatitis.

Entities:  

Year:  1985        PMID: 21279152      PMCID: PMC2327345     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  10 in total

Review 1.  The transmission and outcome of hepatitis A, B, and non-A, non-B: a review.

Authors:  D P Francis; J E Maynard
Journal:  Epidemiol Rev       Date:  1979       Impact factor: 6.222

2.  Immunoprophylaxis of viral hepatitis.

Authors:  L B Seeff; J H Hoofnagle
Journal:  Gastroenterology       Date:  1979-07       Impact factor: 22.682

Review 3.  The hepatitis A virus infection.

Authors:  L R Mathiesen
Journal:  Liver       Date:  1981-06

Review 4.  non-A, Non-B hepatitis. II. Experimental transmission, putative virus agents and markers, and prevention.

Authors:  J L Dienstag
Journal:  Gastroenterology       Date:  1983-09       Impact factor: 22.682

Review 5.  Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features.

Authors:  J L Dienstag
Journal:  Gastroenterology       Date:  1983-08       Impact factor: 22.682

Review 6.  Serologic markers of hepatitis B virus infection.

Authors:  J H Hoofnagle
Journal:  Annu Rev Med       Date:  1981       Impact factor: 13.739

7.  Prevalence of antibody to hepatitis A virus in a Canadian Inuit community.

Authors:  G Y Minuk; J G Waggoner; R Jernigan; L E Nicolle; B Postl; J H Hoofnagle
Journal:  Can Med Assoc J       Date:  1982-11-01       Impact factor: 8.262

8.  Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine.

Authors:  R P Beasley; L Y Hwang; G C Lee; C C Lan; C H Roan; F Y Huang; C L Chen
Journal:  Lancet       Date:  1983-11-12       Impact factor: 79.321

Review 9.  Immunoprophylaxis and treatment of viral hepatitis B.

Authors:  L B Seeff
Journal:  Semin Liver Dis       Date:  1981-02       Impact factor: 6.115

10.  A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report.

Authors:  W Szmuness; C E Stevens; E A Zang; E J Harley; A Kellner
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

  10 in total
  1 in total

1.  Screening homosexual men for hepatitis B.

Authors:  K H Jaczek
Journal:  Can Fam Physician       Date:  1986-04       Impact factor: 3.275

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.